Literature DB >> 18193153

Neuroleptics and animal models: feasibility of oral treatment monitored by plasma levels and receptor occupancy assays.

Emma Perez-Costas1, Paolo Guidetti, Miguel Melendez-Ferro, Joyce J Kelley, Rosalinda C Roberts.   

Abstract

The administration of neuroleptics in animal models has been extensively reported and plays an important role in the study of schizophrenia. Our study was designed to address the following questions: (1) Is it possible to achieve steady-state receptor occupancy levels administering neuroleptics in drinking water? (2) Is there an appropriate dose to obtain clinically comparable receptor occupancies? (3) Is there a correlation between plasma drug levels and receptor occupancy? Thus, we tested three neuroleptic drugs administered in drinking water for 7 days. Plasma drug levels were measured, and in vivo receptor occupancy assays were performed in order to determine peak and trough dopamine D(2) receptor occupancies in striatal brain samples. Overall, our study indicates that in rodents the administration of appropriate doses of haloperidol and olanzapine in drinking water achieves receptor occupancies comparable to the clinical occupancy levels, but this appears not to be the case for clozapine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18193153      PMCID: PMC2410030          DOI: 10.1007/s00702-007-0004-5

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  44 in total

1.  Linear pharmacokinetics of haloperidol in the rat.

Authors:  Y F Cheng; L K Paalzow
Journal:  Biopharm Drug Dispos       Date:  1992-01       Impact factor: 1.627

2.  Scopolamine fails to diminish chronic haloperidol-induced purposeless chewing in rats.

Authors:  K Sakai; X M Gao; C A Tamminga
Journal:  Psychopharmacology (Berl)       Date:  2001-01-01       Impact factor: 4.530

3.  Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection.

Authors:  J T Catlow; R D Barton; M Clemens; T A Gillespie; M Goodwin; S P Swanson
Journal:  J Chromatogr B Biomed Appl       Date:  1995-06-09

4.  Effects of sub-chronic antipsychotic drug treatment on body weight and reproductive function in juvenile female rats.

Authors:  M J Fell; J C Neill; C Rao; K M Marshall
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

5.  Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways.

Authors:  K Sakai; X M Gao; T Hashimoto; C A Tamminga
Journal:  Synapse       Date:  2001-02       Impact factor: 2.562

Review 6.  To model a psychiatric disorder in animals: schizophrenia as a reality test.

Authors:  B K Lipska; D R Weinberger
Journal:  Neuropsychopharmacology       Date:  2000-09       Impact factor: 7.853

7.  Multidose risperidone treatment evaluated in a rodent model of tardive dyskinesia.

Authors:  Xue-Min Gao; Thomas Cooper; Raymond F Suckow; Carol A Tamminga
Journal:  Neuropsychopharmacology       Date:  2005-11-23       Impact factor: 7.853

8.  Chronic treatments with haloperidol and clozapine alter the level of NMDA-R1 mRNA in the rat brain: an in situ hybridization study.

Authors:  Krystyna Ossowska; Małgorzata Pietraszek; Jadwiga Wardas; Marta Dziedzicka-Wasylewska; Dorota Nowicka; Stanisław Wolfarth
Journal:  Pol J Pharmacol       Date:  2002 Jan-Feb

9.  Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs.

Authors:  L Farde; F A Wiesel; C Halldin; G Sedvall
Journal:  Arch Gen Psychiatry       Date:  1988-01

10.  Weight loss dynamics during combined fluoxetine and olanzapine treatment.

Authors:  Jennifer A Perrone; Janet M Chabla; Brian H Hallas; Judith M Horowitz; German Torres
Journal:  BMC Pharmacol       Date:  2004-10-21
View more
  12 in total

1.  Neuroleptics and animal models: feasibility of oral treatment monitored by plasma levels and receptor occupancy assays.

Authors:  Emma Perez-Costas; Paolo Guidetti; Miguel Melendez-Ferro; Joyce J Kelley; Rosalinda C Roberts
Journal:  J Neural Transm (Vienna)       Date:  2008-01-11       Impact factor: 3.575

2.  Phencyclidine-induced loss of asymmetric spine synapses in rodent prefrontal cortex is reversed by acute and chronic treatment with olanzapine.

Authors:  John D Elsworth; Bret A Morrow; Tibor Hajszan; Csaba Leranth; Robert H Roth
Journal:  Neuropsychopharmacology       Date:  2011-06-15       Impact factor: 7.853

3.  Dopamine denervation of the prefrontal cortex increases expression of the astrocytic glutamate transporter GLT-1.

Authors:  Peter J Vollbrecht; Linda D Simmler; Randy D Blakely; Ariel Y Deutch
Journal:  J Neurochem       Date:  2014-03-18       Impact factor: 5.372

4.  Long term antipsychotic treatment does not alter metabolite concentrations in rat striatum: an in vivo magnetic resonance spectroscopy study.

Authors:  Diana M Lindquist; R Scott Dunn; Kim M Cecil
Journal:  Schizophr Res       Date:  2011-03-22       Impact factor: 4.939

5.  Reversal of social deficits by subchronic oxytocin in two autism mouse models.

Authors:  Brian L Teng; Viktoriya D Nikolova; Natallia V Riddick; Kara L Agster; James J Crowley; Lorinda K Baker; Beverly H Koller; Cort A Pedersen; Michael B Jarstfer; Sheryl S Moy
Journal:  Neuropharmacology       Date:  2015-12-31       Impact factor: 5.250

6.  Olanzapine treatment of adolescent rats alters adult reward behaviour and nucleus accumbens function.

Authors:  Monika Vinish; Ahmed Elnabawi; Jean A Milstein; Jesse S Burke; Jonathan K Kallevang; Kevin C Turek; Carien S Lansink; Istvan Merchenthaler; Aileen M Bailey; Bryan Kolb; Joseph F Cheer; Douglas O Frost
Journal:  Int J Neuropsychopharmacol       Date:  2013-01-25       Impact factor: 5.176

7.  A role for dopamine D2 receptors in reversal learning.

Authors:  D A De Steno; C Schmauss
Journal:  Neuroscience       Date:  2009-05-03       Impact factor: 3.590

8.  Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia.

Authors:  Urs Meyer; Erica Spoerri; Benjamin K Yee; Markus J Schwarz; Joram Feldon
Journal:  Schizophr Bull       Date:  2008-10-08       Impact factor: 9.306

9.  Dystrophic dendrites in prefrontal cortical pyramidal cells of dopamine D1 and D2 but not D4 receptor knockout mice.

Authors:  Hui-Dong Wang; Gregg D Stanwood; David K Grandy; Ariel Y Deutch
Journal:  Brain Res       Date:  2009-09-10       Impact factor: 3.252

10.  Olanzapine treatment of adolescent rats causes enduring specific memory impairments and alters cortical development and function.

Authors:  Jean A Milstein; Ahmed Elnabawi; Monika Vinish; Thomas Swanson; Jennifer K Enos; Aileen M Bailey; Bryan Kolb; Douglas O Frost
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.